AIMS: After Danish nationwide investigations (1987, 1989) demonstrated unacceptable blood glucose control in unselected young diabetic patients, we set out to estimate the present glycaemic control and the prevalence of microvascular complications in a cohort of children and adolescents participating in the two previous studies. METHODS: This follow-up represents 339 patients (47% of the inception cohort), median age 21.1 years (range 12.0-26.9), median diabetes duration 13.2 years (range 8.9-24.5). A standardized questionnaire, fundus photographs (with central reading) and a physical examination were performed. HbA1c and overnight albumin excretion rate (AER) were analysed centrally. RESULTS: Although 88% (n= 309) of the young persons were treated with three or more daily insulin injections, HbA1c (nondiabetic range 4.3-5.8, mean 5.3%) was 9.7+/-1.7% (mean+/-SD). Males had higher HbA1c values than females (P < 0.015). Mean daily insulin dose was 0.92+/-0.25 IU.kg(-1).24h(-1). Microalbuminuria (AER > 20-150 microg/min) and macroalbuminuria (AER > 150 microg/min) were found in 9.0% and 3.7% of the patients, respectively, and was associated with increased diastolic blood pressure (P<0.01) and presence of retinopathy (P<0.01). Retinopathy was present in approximately 60% of the patients and was associated with age, diabetes duration, HbA1c, diastolic blood pressure and AER (all P<0.01). Subclinical neuropathy (vibration perception threshold by biothesiometry > 6.5 V) was found in 62% and showed a significant association with age, linear height, diastolic blood pressure (all P < 0.01) and diabetic retinopathy (P = 0.01). CONCLUSIONS: In spite of the majority of the patients being on multiple insulin injections, only 11% had HbA1c values below 8% and the prevalence of diabetic microvascular complications in kidneys, eyes and nerves was unacceptable high.
AIMS: After Danish nationwide investigations (1987, 1989) demonstrated unacceptable blood glucose control in unselected young diabeticpatients, we set out to estimate the present glycaemic control and the prevalence of microvascular complications in a cohort of children and adolescents participating in the two previous studies. METHODS: This follow-up represents 339 patients (47% of the inception cohort), median age 21.1 years (range 12.0-26.9), median diabetes duration 13.2 years (range 8.9-24.5). A standardized questionnaire, fundus photographs (with central reading) and a physical examination were performed. HbA1c and overnight albumin excretion rate (AER) were analysed centrally. RESULTS: Although 88% (n= 309) of the young persons were treated with three or more daily insulin injections, HbA1c (nondiabetic range 4.3-5.8, mean 5.3%) was 9.7+/-1.7% (mean+/-SD). Males had higher HbA1c values than females (P < 0.015). Mean daily insulin dose was 0.92+/-0.25 IU.kg(-1).24h(-1). Microalbuminuria (AER > 20-150 microg/min) and macroalbuminuria (AER > 150 microg/min) were found in 9.0% and 3.7% of the patients, respectively, and was associated with increased diastolic blood pressure (P<0.01) and presence of retinopathy (P<0.01). Retinopathy was present in approximately 60% of the patients and was associated with age, diabetes duration, HbA1c, diastolic blood pressure and AER (all P<0.01). Subclinical neuropathy (vibration perception threshold by biothesiometry > 6.5 V) was found in 62% and showed a significant association with age, linear height, diastolic blood pressure (all P < 0.01) and diabetic retinopathy (P = 0.01). CONCLUSIONS: In spite of the majority of the patients being on multiple insulin injections, only 11% had HbA1c values below 8% and the prevalence of diabetic microvascular complications in kidneys, eyes and nerves was unacceptable high.
Authors: R Valdes-Gonzalez; A L Rodriguez-Ventura; D J G White; E Bracho-Blanchet; A Castillo; B Ramírez-González; M G López-Santos; B H León-Mancilla; L M Dorantes Journal: Clin Exp Immunol Date: 2010-10-21 Impact factor: 4.330
Authors: Rebecca Broe; Malin L Rasmussen; Ulrik Frydkjaer-Olsen; Birthe S Olsen; Henrik B Mortensen; Tunde Peto; Jakob Grauslund Journal: Diabetologia Date: 2014-07-01 Impact factor: 10.122
Authors: N Minuto; V Emmanuele; M Vannati; C Russo; C Rebora; S Panarello; A Pistorio; R Lorini; G d'Annunzio Journal: J Endocrinol Invest Date: 2011-10-06 Impact factor: 4.256
Authors: M L Rasmussen; R Broe; U Frydkjaer-Olsen; B S Olsen; H B Mortensen; T Peto; J Grauslund Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-08-12 Impact factor: 3.117
Authors: M L Rasmussen; R Broe; U Frydkjaer-Olsen; B S Olsen; H B Mortensen; T Peto; J Grauslund Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-06-05 Impact factor: 3.117
Authors: Steffen U Thorsen; Kristian Sandahl; Lotte B Nielsen; Rebecca Broe; Malin L Rasmussen; Tunde Peto; Jakob Grauslund; Marie L M Andersen; Henrik B Mortensen; Flemming Pociot; Birthe S Olsen; Caroline Brorsson Journal: Graefes Arch Clin Exp Ophthalmol Date: 2015-08-06 Impact factor: 3.117
Authors: Mamta Jaiswal; Abigail Lauer; Catherine L Martin; Ronny A Bell; Jasmin Divers; Dana Dabelea; David J Pettitt; Sharon Saydah; Catherine Pihoker; Debra A Standiford; Beatriz L Rodriguez; Rodica Pop-Busui; Eva L Feldman Journal: Diabetes Care Date: 2013-10-21 Impact factor: 19.112